Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2018 and 2017 were as follows (in thousands):

	September 30, 2018
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	41,403	$	—	$	(51	)	$	41,352
Total	$	41,403	$	—	$	(51	)	$	41,352

	September 30, 2017
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	31,817	$	—	$	(15	)	$	31,802
Total	$	31,817	$	—	$	(15	)	$	31,802

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2018		2017
Raw materials	$	1,890	$	1,603
Work in-process		780		659
Finished products		1,346		1,254
Total	$	4,016	$	3,516

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2018			2017
	(In years)
Land	N/A	$	4,420		$	4,420
Laboratory fixtures and equipment	3 to 10		22,024			19,491
Buildings and improvements	3 to 20		21,717			21,924
Leasehold improvements	10		4,836			—
Office furniture and equipment	3 to 10		5,824			4,541
Construction-in-progress			4,834			2,493
Less accumulated depreciation			(33,512	)		(29,927	)
Property and equipment, net		$	30,143		$	22,942

Summary of Other Assets

Other assets consist principally of the following as of September 30 (in thousands):

	2018		2017
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		967		418
Other assets, net	$	1,446	$	897

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2018
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	18,086	$	(9,377	)	$	8,709
Developed technology		11.5		9,656		(2,361	)		7,295
Non-compete		5.0		230		(150	)		80
Patents and other		16.5		2,321		(1,569	)		752
Subtotal				30,293		(13,457	)		16,836
Unamortized intangible assets:
In-process research and development				267		—			267
Trademarks and trade names				580		—			580
Total			$	31,140	$	(13,457	)	$	17,683

	2017
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	18,293	$	(7,834	)	$	10,459
Developed technology		11.7		9,297		(1,478	)		7,819
Non-compete		5.0		230		(103	)		127
Patents and other		16.5		2,321		(1,423	)		898
Subtotal				30,141		(10,838	)		19,303
Unamortized intangible assets:
In-process research and development				679		—			679
Trademarks and trade names				580		—			580
Total			$	31,400	$	(10,838	)	$	20,562

Estimated Amortization Expense

Based on the intangible assets in service, excluding any possible future amortization associated with acquiredin process research and development (“IPR&D”), which has not met technological feasibility as of September 30, 2018, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2019	$	2,690
2020		2,514
2021		2,375
2022		2,336
2023		1,737

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the years ended September 30, 2018 and 2017 was as follows (in thousands):

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Foreign currency translation adjustment		—		727			727
Balance as of September 30, 2017		8,010		19,272			27,282
Foreign currency translation adjustment		—		(250	)		(250	)
Balance as of September 30, 2018	$	8,010	$	19,022		$	27,032

Schedule of Other Accrued Liabilities

Other accrued liabilities consisted of the following as of September 30 (in thousands):

	2018		2017
Accrued professional fees	$	311	$	501
Accrued clinical study expense		2,839		411
Accrued purchases		533		596
Customer claim		1,000		—
Construction in progress		1,199		—
Deferred rent		121		18
Other		262		247
Total	$	6,265	$	1,773

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share for each of the years ended September 30 (in thousands):

	2018			2017		2016
Net income from continuing operations available to    common shareholders	$	(4,457	)	$	3,926	$	9,985
Basic weighted average shares outstanding		13,157			13,153		12,998
Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units and performance    shares		—			236		221
Diluted weighted average shares outstanding		13,157			13,389		13,219